Axonics, Inc. Common Stock
AXNX
AXNX was delisted on the 14th of November, 2024.
81 hedge funds and large institutions have $261M invested in Axonics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 30 increasing their positions, 14 reducing their positions, and 12 closing their positions.
114% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 14
92% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 12
14% more funds holding
Funds holding: 71 → 81 (+10)
0% more call options, than puts
Call options by funds: $13K | Put options by funds: $13K
34% less capital invested
Capital invested by funds: $394M → $261M (-$133M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$16.1M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$6.89M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$5.06M |
| 4 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$4.69M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$3.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$12.8M |
| 2 |
PA
Perceptive Advisors
New York
|
-$11.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.6M |
| 4 |
JP Morgan Chase
New York
|
-$8.12M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$6.88M |
AXNX Hedge Fund Activity: Q3 2019 in Review
81 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Axonics, Inc. Common Stock (AXNX) for Q3 2019, worth a combined $261M — down 34% from $394M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new AXNX positions and 12 closed out — a net gain of 11 holders — while 30 added to existing stakes and 14 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $16.1M. The largest seller was Goldman Sachs, cutting an estimated $12.8M.
- 81 institutional investors held Axonics, Inc. Common Stock (AXNX) as of Q3 2019, up from 71 in Q2 2019.
- Funds reported $261M of Axonics, Inc. Common Stock stock for Q3 2019, down 34% quarter-over-quarter.
- 23 funds opened new Axonics, Inc. Common Stock positions in Q3 2019 and 12 closed out, a net change of +11 holders.
- The largest Axonics, Inc. Common Stock buyer in Q3 2019 was Citadel Advisors, an estimated $16.1M added.
- The largest Axonics, Inc. Common Stock seller in Q3 2019 was Goldman Sachs, an estimated $12.8M sold.
Based on aggregated 13F filings for Q3 2019.